Ursodeoxycholic acid in primary sclerosing cholangitis: If withdrawal is bad, then administration is good (right?)

Hepatology

Volumn 60, Issue 3, 2014, Pages 785-788

  Tabibian, James H ^a   Lindor, Keith D ^b  

^a MAYO CLINIC   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; BILIRUBIN; BIOLOGICAL MARKER; CHOLESTEROL 7ALPHA MONOOXYGENASE; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR 19; NONSTEROID ANTIINFLAMMATORY AGENT; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHROPATHY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE ACID SYNTHESIS; BILIARY TRACT ENDOSCOPY; BILIRUBIN BLOOD LEVEL; BLOOD; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DEATH; DETERIORATION; DRUG EFFECT; DRUG USE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; HEALING; HISTORY; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; NEGATIVE FEEDBACK; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; QUALITY OF LIFE; REMISSION; SHORT FORM 36; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

BILE ACIDS AND SALTS; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; FEMALE; HUMANS; MALE; URSODEOXYCHOLIC ACID;

EID: 84906794995     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27180     Document Type: Article

References (20)

1. Tabibian JH, Lindor KD. Primary sclerosing cholangitis: a review and update on therapeutic developments. Exp Rev Gastroenterol Hepatol 2013;7:103-114.
2. Pollheimer MJ, Halilbasic E, Fickert P, Trauner M. Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2011;25:727-739.
3. Tabibian JH, O'Hara SP, Splinter PL, Trussoni CE, Larusso NF. Cholangiocyte senescence via N-Ras activation is a characteristic of primary sclerosing cholangitis. Hepatology 2014;59:2263-2275.
4. Tabibian JH, Lindor KD. Challenges of cholangiocarcinoma detection in patients with primary sclerosing cholangitis. J Analyt Oncol 2012;1:50-55.
5. Wiesner RH, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989;10:430-436.
6. Bjoro K, Brandsaeter B, Foss A, Schrumpf E. Liver transplantation in primary sclerosing cholangitis. Semin Liver Dis 2006;26:69-79.
7. Alabraba E, Nightingale P, Gunson B, Hubscher S, Olliff S, Mirza D, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009;15:330-340.
8. Aberg F, Hockerstedt K, Roine RP, Sintonen H, Isoniemi H. Influence of liver-disease etiology on long-term quality of life and employment after liver transplantation. Clin Transplant 2012;26:729-735.
9. Benito de Valle M, Rahman M, Lindkvist B, Bjornsson E, Chapman R, Kalaitzakis E. Factors that reduce health-related quality of life in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2012;10:769-775.e2.
10. Hagey LR, Crombie DL, Espinosa E, Carey MC, Igimi H, Hofmann AF. Ursodeoxycholic acid in the Ursidae: biliary bile acids of bears, pandas, and related carnivores. J Lipid Res 1993;34:1911-1917.
11. Hofmann AF. Bile acids: trying to understand their chemistry and biology with the hope of helping patients. Hepatology 2009;49:1403-1418.
12. Chazouilleres O, Poupon R, Capron JP, Metman EH, Dhumeaux D, Amouretti M, et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 1990;11:120-123.
13. Stanich PP, Bjornsson E, Gossard AA, Enders F, Jorgensen R, Lindor KD. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis 2011;43:309-313.
14. Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992;16:707-714.
15. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808-814.
16. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-907.
17. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005;129:1464-1472.
18. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-678.
19. Beuers U, Boberg KM, Chapman RW, Chazouillères O, Invernizzi P, Jones DE, et al. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237-267.
20. Wunsch E, Trottier J, Milkiewicz M, Raszeja-Wyszomirska J, Hirschfield GM, Barbier O, et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology 2014;60:931-940.